Key result
Cold-adapted EV71 vaccine candidate induces robust humoral immunity without clinical or pathological illness in primates.
Why the study?
Enterovirus A71 causes hand foot and mouth disease with potentially fatal neurological complications, making the development of safe, cost-effective vaccines a major public health priority.
Does a stable, cold-adapted EV-A71 strain produce a safe and immunogenic response in a monkey model?
Does a stable, cold-adapted EV-A71 strain produce a safe and immunogenic response in a monkey model?
This cold-adapted EV-A71 strain demonstrates phenotypic stability, safety, and immunogenicity in a monkey model, showing potential as a live attenuated vaccine candidate.
Hypothesis-generating for cold-adapted EV-A71 live vaccine; human trials needed before clinical consideration.
Enterovirus A71 (EV-A71) and coxsackievirus A16 (CA16) are major etiological agents of hand foot and mouth disease (HFMD) in children, which may result in fatal neurological complications. The development of safe, cost effective vaccines against HFMD, especially for use in developing countries, is still a top public health priority. We have successfully generated a stable, cold-adapted, temperature sensitive/conditional lethal EV-A71 through adaptive culturing in Vero cells at incrementally lower cultivation temperatures. An additional 40 passages at an incubation temperature of 28 °C, and a temperature reversion study at an incubation temperature of 37 °C and 39.5 °C, reveals the virus's phenotypic and genetic stability at the predefined culture conditions. Six unique mutations (two in noncoding regions and four in nonstructural protein-coding genes) in combination may have contributed to its stable phenotype and inability to fully revert to its original wild phenotype. The safety and immunogenicity of this stable, cold-adapted, temperature sensitive/conditional lethal EV-A71 was performed in six monkeys. None of the inoculated monkeys developed any obvious clinical illness except one which developed a transient spike of fever. No gross postmortem lesion or abnormal histological finding was noted for all monkeys at autopsy. No virus was reisolated although EV-A71 specific RNA was detected in serum samples collected on both day 4 and day 8 postinoculation. Only EV-A71 RNA and viral antigen were detected in the spleen homogenate and peripheral blood mononuclear cells, respectively, collected on day 4. The two remaining monkeys developed good humoral immune response on day 14 and day 30 post-inoculation.
No takes yet. Share an insight, caveat, or question.
Chua et al. (2021) studied Enterovirus A71 (EV-A71) infection model (n=7). EV71:TLLβP20 (cold-adapted, temperature-sensitive EV-A71 strain) vs. Negative control was evaluated on Safety (clinical illness and histological lesions) and immunogenicity (humoral immune response). The cold-adapted EV71:TLLβP20 strain elicited a good humoral immune response in monkeys without causing obvious clinical illness or pathological lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: